Inequities in Access to Omalizumab for Pediatric Food Allergy Patients

A new study from Children's National, published in Pediatric Allergy and Immunology, is drawing attention to who is — and who is not — reaching omalizumab in the early years after its 2024 FDA approval for pediatric food allergy. In the landmark trial supporting approval, 67% of treated children tolerated small amounts of multiple food allergens after four months, a meaningful shift in the management pathway for a chronic condition that places enormous daily burden on patients and families. For pediatric immunology teams who have long awaited a monoclonal antibody that blocks circulating IgE, the real-world uptake data should give every clinician pause.

The early uptake pattern

The research team, led by Tiffany Kichline, PhD, reviewed records from the Children's National Food Allergy Clinic and compared 56 children who started omalizumab against the 3,112 food allergy patients seen during the same period. The clinical presentation of those receiving treatment was reassuring in one respect: these were the children we would most want to see prioritized. More than 91% had multiple food allergies, and nearly 73% had a documented history of anaphylaxis. Both findings suggest that the sickest patients — those carrying the heaviest immune-mediated burden — are being identified and referred.

The demographic picture alongside it is harder to read. Children started on omalizumab were far more likely to identify as White (69.6% versus 26.0% across the broader clinic population), less likely to identify as Black (8.9% versus 37.8%), and less likely to identify as Hispanic (7.1% versus 20.0%). Nearly 90% of those receiving treatment carried private insurance, compared with 55.3% of the clinic as a whole. These are not small gradients, and they sit squarely on top of a therapy that requires monthly infusions, specialty follow-up, and sustained caregiver commitment.

What we should investigate next

These gaps point to real clinical questions, and the authors are right to flag them. We still do not know whether the disparities reflect which families hear about the therapy, which can absorb the treatment burden of repeated visits, which have specialty access in the first place, or which can navigate prior authorization and out-of-pocket cost. Each of these deserves its own line of inquiry, and we should not conflate them.

For us at the bedside, the practical work begins now. As omalizumab moves from trial into routine clinical practice, we should be auditing our own patient panels: who is being offered this therapy, who is declining after a shared decision-making conversation, and who is never hearing about it. Longer-term quality of life outcomes, anxiety reduction around accidental allergen exposure, and the day-to-day management load on caregivers all still require longitudinal study — but the equitable dissemination of an already-approved, already-reimbursed option is a question we can begin answering in our own clinics today.